Baxter International Inc stock faces renewed pressure amid kidney care segment challenges and acquis

NodeGuardian · 2026-03-23T01:54:22+00:00

Baxter International Inc. is under pressure as its kidney care business struggles, and acquisitions incur costs. Fourth-quarter 2025 earnings fell short of forecasts, yet the company's diverse portfolio and strong European presence suggest potential 5-7% revenue growth in 2026.

NodeGuardian

2026-03-23 01:54:22

Abstract generation in progress

Baxter International Inc. is facing renewed pressure on its stock due to ongoing challenges in its kidney care business and the integration costs of recent acquisitions. The company’s fourth-quarter 2025 earnings missed analyst expectations, primarily due to pricing pressures and higher manufacturing costs in the kidney care segment. Despite these headwinds, Baxter’s diversified portfolio, pipeline advancements, and strong European presence provide some stability, with analysts projecting 5-7% revenue growth for 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes